Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SLDB 
Solid Biosciences LLC (SLDB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SLDB (3-star) is a SELL. SELL since 4 days. Profits (33.92%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.58
1 Year Target Price $15.58
| 7 | Strong Buy |
| 5 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 140.32% | Avg. Invested days 44 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 475.78M USD | Price to earnings Ratio - | 1Y Target Price 15.58 |
Price to earnings Ratio - | 1Y Target Price 15.58 | ||
Volume (30-day avg) 12 | Beta 2.44 | 52 Weeks Range 2.41 - 10.37 | Updated Date 08/15/2025 |
52 Weeks Range 2.41 - 10.37 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.79 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.35% | Return on Equity (TTM) -68.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 230721023 | Price to Sales(TTM) 3.65 |
Enterprise Value 230721023 | Price to Sales(TTM) 3.65 | ||
Enterprise Value to Revenue 1.16 | Enterprise Value to EBITDA -3.69 | Shares Outstanding 77869104 | Shares Floating 33065544 |
Shares Outstanding 77869104 | Shares Floating 33065544 | ||
Percent Insiders 0.52 | Percent Institutions 106.1 |
Upturn AI SWOT
Solid Biosciences LLC
Company Overview
History and Background
Solid Biosciences LLC was founded in 2013. It is a biotechnology company focused on developing therapies for Duchenne muscular dystrophy (DMD). Significant milestones include initiating clinical trials for their lead product candidate, SGT-001, and navigating regulatory challenges.
Core Business Areas
- Gene Therapy Development: Solid Biosciences focuses on developing gene therapies for DMD, particularly using adeno-associated virus (AAV) vectors to deliver a functional dystrophin gene to muscle cells.
Leadership and Structure
Ilan Ganot is the CEO. The company has a board of directors and is structured around research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- SGT-001 (now known as GT-AAV9-Dystrophin): SGT-001 is an investigational gene therapy for DMD. Market share is not applicable as it is still in clinical development. Competitors include Sarepta Therapeutics (SRPT) with Elevidys and Vertex Pharmaceuticals (CRSP) (collaboration with CRSP).
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, with increasing investment and regulatory approvals. The DMD market is a significant segment due to the unmet medical need.
Positioning
Solid Biosciences is positioned as a company focused on gene therapy for DMD, aiming to provide a potentially disease-modifying treatment. Their competitive advantage is their gene therapy approach.
Total Addressable Market (TAM)
The DMD market is estimated to be several billion dollars annually. Solid Biosciences aims to capture a significant portion of this market with a successful gene therapy.
Upturn SWOT Analysis
Strengths
- Gene therapy platform
- Focus on DMD
- Experienced leadership team
- Novel therapeutic approach
Weaknesses
- Clinical trial setbacks
- Regulatory hurdles
- High development costs
- Limited cash runway
Opportunities
- Positive clinical trial results
- Regulatory approval
- Partnerships and collaborations
- Expansion to other indications
Threats
- Clinical trial failures
- Competition from other therapies
- Regulatory delays
- Adverse events
Competitors and Market Share
Key Competitors
- SRPT
- VRTX
- PTCT
Competitive Landscape
Solid Biosciences faces strong competition from established pharmaceutical companies and other gene therapy developers. Their advantage lies in their novel gene therapy approach, but they face challenges in demonstrating safety and efficacy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancements in clinical trials and preclinical studies, but no revenue growth.
Future Projections: Future growth depends on the success of their gene therapy program and potential regulatory approval. Analyst estimates vary based on clinical trial results.
Recent Initiatives: Recent initiatives include advancing their gene therapy candidate through clinical trials and addressing safety concerns raised by regulatory agencies.
Summary
Solid Biosciences is a biotechnology company focused on developing gene therapies for Duchenne muscular dystrophy. The company faces challenges related to clinical trial setbacks and regulatory hurdles. Its success hinges on the successful development and approval of their gene therapy candidate. Cashflow issues are a concern. Regulatory hurdles must be cleared.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Solid Biosciences LLC
Exchange NASDAQ | Headquaters Charlestown, MA, United States | ||
IPO Launch date 2018-01-26 | President, CEO & Director Mr. Alexander G. Cumbo | ||
Sector Healthcare | Industry Biotechnology | Full time employees 100 | Website https://www.solidbio.com |
Full time employees 100 | Website https://www.solidbio.com | ||
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.